Comment by after_care

I concur with the core message -- that the current research on psychedelics is not strong. Some of the problem is that the research itself was not designed with an eye on earning FDA approval. This was hard to do because we'll never have a true double-blind psychedelic trial for psychedelics like we can have for SSRIs. Spravato recently showed a path for FDA approval, because ketamine treatment for depression closely mirrors protocols for psychedelics.